The content on this site is intended for healthcare professionals only
Tarlatamab improves long term survival in previously treated small cell lung cancer
ABBV-706 shows promising antitumour activity in R/R SCLC
Divarasib improves survival in previously treated KRAS G12C mutated advanced NSCLC
Tarlatamab plus durvalumab improves survival in extensive-stage small cell lung cancer
Real-world outcomes with tarlatamab in previously treated ES-SCLC
Reduced dosing frequency of immune checkpoint inhibitors raises survival concerns in advanced cancer
ESMO 2026: Highlights and analysis
Tarlatamab's role in SCLC
WCLC 2026: Lung cancer research highlights
Izalontamab brenitecan shows promising activity in previously treated EGFR mutated NSCLC
Zidesamtinib shows promising efficacy in TKI-naïve ROS1-positive advanced NSCLC
Using artificial intelligence to improve lung cancer screening and risk prediction
